ミシガン州における転移性癌の臨床試験
ミシガン州内の拠点で、転移性癌に関する51件の研究が参加者を募集しています。
ミシガン州内の都市
公式研究テキスト（英語）
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- University of Michigan Rogel Cancer Center, Ann Arbor
- Bronson Battle Creek, Battle Creek
- 他37件
被験者募集中第2相
全年齢 · 全性別 · 2026/10/02更新 · NCT05564377A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- START Midwest Cancer and Hematology Centers of W Michigan, Grand Rapids
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06465069A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- South Texas Accelerated Research Therapeutics (START), Grand Rapids
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06270706A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours
- START Midwest, Grand Rapids
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07213817A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
- ALX Center 8, Farmington Hills
- ALX Center 3, Grand Rapids
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07085091A Study of ASP3082 in Adults With Advanced Solid Tumors
- Trinity Health Ann Arbor Hospital, Ypsilanti
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/30更新 · NCT05382559Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
- Henry Ford Cancer- Detroit, Detroit
- The Cancer and Hematology Centers, Grand Rapids
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/29更新 · NCT06943755Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
- The Cancer & Hematology Centers, Big Rapids
- The Cancer & Hematology Centers, Grand Rapids
- The Cancer & Hematology Centers, Grand Rapids
- 他2件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07222800A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, Detroit
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06103864ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- University of Michigan Rogel Cancer Center, Ann Arbor
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07007559A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
- Henry Ford Cancer Institute, Detroit
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/09/24更新 · NCT05118789Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
- Karmanos Cancer Institute, Detroit
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/23更新 · NCT06915753A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
- Karmanos Cancer Institute, Detroit
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07218380Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- START Midwest, Grand Rapids
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06128551A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Barbara Ann Karmanos Cancer Institute, Detroit
- BAMF Health Inc., Grand Rapids
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07114601A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Karmanos Cancer Institute, Detroit
- West Michigan Cancer Center, Kalamazoo
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07213804A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
- University of Michigan Medical School Rogel Cancer Center, Ann Arbor
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/21更新 · NCT07629960Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- START Midwest, Grand Rapids
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/18更新 · NCT05267626A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
- University of Michigan ( Site 0021), Ann Arbor
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/17更新 · NCT06863272CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
- Clinical Study Site, Detroit
- Clinical Study Site, Grand Rapids
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/10更新 · NCT07335497A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- University of Michigan, Ann Arbor
- The Cancer & Hematology Centers, Grand Rapids
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/08更新 · NCT06119581A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
- South Texas Accelerated Research Therapeutics (START) - Midwest, Grand Rapids
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/03更新 · NCT07213830A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/28更新 · NCT07029399A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Henry Ford Cancer Institute/Henry Ford Health System, Detroit
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/21更新 · NCT06769698FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
- Barbara Ann Karmanos Cancer Institute, Detroit
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/20更新 · NCT05614739A Study of MGC026 in Participants With Advanced Solid Tumors
- START Midwest, Grand Rapids
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/11更新 · NCT06242470A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors
- START Midwest, Grand Rapids
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/10更新 · NCT06880549A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
- Crinetics Study Site, Detroit
- Crinetics Study Site, Grand Rapids
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/31更新 · NCT07129252Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
- Research Site, Ann Arbor
- Research Site, Ann Arbor
被験者募集中第3相
18歳以上 · 女性 · 2026/07/29更新 · NCT07044336A Study of ASP1002 in Adults for Treatment of Solid Tumors
- Henry Ford Hospital, Detroit
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/23更新 · NCT05719558Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
- Investigative Site #120, Detroit
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/23更新 · NCT06974110A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
- Henry Ford Health System, Detroit
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/15更新 · NCT06657144Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
- Henry Ford Hospital, Detroit
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/07/14更新 · NCT05533697Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
- VA Ann Arbor Healthcare System, Ann Arbor
被験者募集中第2相
18歳以上 · 男性 · 2026/06/15更新 · NCT05422911CT-95 in Advanced Cancers Associated With Mesothelin Expression
- Context Investigational Site, Grand Rapids
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/12更新 · NCT06756035Laser Interstitial Thermal Ablation and Stereotactic Radiosurgery for Patients With Spine Metastases
- Henry Ford Hospital, Detroit
被験者募集中
18歳以上 · 全性別 · 2026/06/03更新 · NCT05023772A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
- Henry Ford Cancer Institute, Detroit
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/05/27更新 · NCT05384626Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
- Henry Ford Health System, Detroit
被験者募集中第3相
18歳以上 · 全性別 · 2026/05/18更新 · NCT06757634A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
- START Midwest, Grand Rapids
被験者募集中第1相
18歳以上 · 全性別 · 2026/05/18更新 · NCT07094204A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
- Start Midwest Cancer Research, Grand Rapids
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/04/28更新 · NCT06413680ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。